Landscapes / Companies
Qurient Co., Ltd. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 2
Drugs
2
in active trials · 3 in all
Trials
3 active
5 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
Phase 1/2 | 30 Dec 2027Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Esophageal Cancer, Gastric Cancer and 3 more | ||||
| Open drug page | |||||
Mocaciclibnot checked |
Cyclin-dependent kinase inhibitor |
Phase 1/2 | 31 Mar 2029Phase 1/2 trial completes | ||
| How it works | Blocks CDK enzymes that let cells divide | ||||
| Next date | 31 Mar 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Cancer, Metastatic Cancer | ||||
| Open drug page | |||||
About
- No active trial
- Telacebec
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021